BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

BioCardia, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.90−0.02 (-2.46%)

Close on Oct 19, 2026

Market cap: $10.85M
P/E (TTM): –
Dividend yield: –

Community

Notes and questions about BioCardia from other investors

No posts about BCDA yet

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in BioCardia's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on May 30, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BCDA.

Company	Revenue	Growth
CELZ	$3.00K	-50.0%
BCDA	$0	-100.0%
TNYA	–	–
ALLO	–	–
SNTI	–	–
SANA	–	–

Company

Next earnings (est.): Nov 11, 2026, after close
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 21
Held by institutions: 8.8%
Auditor: PKF San Diego, LLP
SEC CIK: 925741

Advertisement
300 × 250